Department of Pediatrics

Pediatric Retrovirology Research


Research Projects

Media Component

Research projects focus on the diagnosis and treatment of childhood tuberculosis in the international setting, the elimination of HIV transmission to at-risk youth, best practices of HIV mother-to-child transmission prevention, treatment of HIV infection in infants, children, adolescents, and young adults, and outcomes in perinatally HIV-infected youth. View information about our international research conducted by Baylor International Pediatric AIDS Initiative (BIPAI).

Pediatric Retrovirology operates within the Section of Immunology, Allergy and Retrovirology and conducts clinical studies sponsored by the NIH through three Networks. The Adolescent Trials Network conducts independent and collaborative research that explores promising behavioral, microbicidal, prophylactic, therapeutic, and vaccine modalities in HIV-infected and at-risk adolescents, ages 12 years through 24 years.

The International Maternal Pediatric Adolescent AIDS Clinical Trials Group’s research work is in the area of improving health outcomes for infants, children and adolescents, and pregnant/postpartum women who are impacted by or living with HIV by evaluating novel treatments and interventions for HIV and it’s complications and for tuberculosis and other HIV-related conditions. Lastly, the Pediatric HIV/ AIDS cohort is a longitudinal cohort study investigating the long-term effects of HIV and antiretroviral medications in children and young adults who were born with HIV or born exposed to HIV. The study follows newborns, young children, adolescents, and young adults.


Clinical Trials

  • AMC 072: Protective effect of quadrivalent vaccine in young HIV positive males who have sex with males.
  • ATN 095: Connect to Protect (C2P) implements a community mobilization intervention, which entails developing coalitions to plan for and bring about structural changes for purposes of reducing HIV incidence and prevalence among youth.
  • ATN 110: Project PrEPare is an open-label demonstration project and phase II safety study of pre-exposure prophylaxis use among young men who have sex with men.
  • ATN 116: Structural enhancements to the strategic multi-site initiative for identification, linkage, and engagement-to-care (SMILE) program.
  • IMPAACT P1026S: Pharmacokinetic properties of antiretroviral therapy during pregnancy.
  • IMPAACT P1080: Mary E. Paul, M.D. is the vice chair of this study entitled, A Pilot Study of Psychiatric and Antiretroviral Medication Concentrations in HIV-1 Infected and Uninfected Children and Adolescents.
  • IMPAACT P1093: Phase I/II, multi-center, open-label, pharmacokinetic, safety, tolerability and antiviral activity of GSK1349572; a novel integrase inhibitor, in combination regimens in HIV-1 infected infants, children and adolescents.
Back to topback-to-top